We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunomedics' Shares Rise on Positive Breast Cancer Drug Data
Read MoreHide Full Article
Shares of Immunomedics Inc. grew 8.2% after the confirmatory phase III study of its breast-cancer drug, Trodelvy (sacituzumab govitecan-hziy), met its primary and secondary endpoints. Moreover, shares of the company have surged 92% year to date compared with the industry’s growth of 11.7%.
The ASCENT study was conducted on brain metastasis negative patients with metastatic triple-negative breast cancer (mTNBC) who had previously received at least two prior therapies for metastatic disease.
In the study, Trodelvy demonstrated a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to chemotherapy, with a hazard ratio of 0.41. The median PFS for patients treated with Trodelvy was 5.6 months compared to 1.7 months for chemotherapy.
The drugalso met key secondary endpoints inthe study, including overall survival and objective response rate.
The data suggest that Trodelvy has set a new benchmark for patients with mTNBC by offering a novel alternative to the common drugs currently in use. The data also validates the manageable safety profile of Trodelvy, thus making it a good option for a partner candidate for combination with other therapies, including immunotherapy.
The phase III results support the previously reported phase II data that formed the basis of the accelerated approval of Trodelvy.
We remind investors that in April, Trodelvy obtained accelerated approval from the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC), who have received at least two prior therapies for metastatic disease. Trodelvy is the first antibody-drug conjugate (ADC) approved by the FDA specifically for previously-treated mTNBC and also the first FDA-approved anti-Trop-2 ADC.
The drug is also being evaluated for additional indications. The FDA recently granted a Fast Track designation to sacituzumab govitecan for the treatment of adult patients with locally-advanced or metastatic urothelial cancer (mUC).
Meanwhile, Immunomedics also collaborated with few companies for further development of Trodelvy. Itcollaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s (MRK - Free Report) anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company also entered two clinical collaborations. It collaborated with Roche (RHHBY - Free Report) to develop Trodelvy in the front-line setting of mTNBC in combination with the latter’s PD-L1 inhibitor, Tecentriq.
The company has a similar collaboration agreement with AstraZeneca (AZN - Free Report) to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
These collaborations are constant sources of funds for the company.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all. This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025. Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Image: Bigstock
Immunomedics' Shares Rise on Positive Breast Cancer Drug Data
Shares of Immunomedics Inc. grew 8.2% after the confirmatory phase III study of its breast-cancer drug, Trodelvy (sacituzumab govitecan-hziy), met its primary and secondary endpoints. Moreover, shares of the company have surged 92% year to date compared with the industry’s growth of 11.7%.
The ASCENT study was conducted on brain metastasis negative patients with metastatic triple-negative breast cancer (mTNBC) who had previously received at least two prior therapies for metastatic disease.
In the study, Trodelvy demonstrated a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to chemotherapy, with a hazard ratio of 0.41. The median PFS for patients treated with Trodelvy was 5.6 months compared to 1.7 months for chemotherapy.
The drugalso met key secondary endpoints inthe study, including overall survival and objective response rate.
The data suggest that Trodelvy has set a new benchmark for patients with mTNBC by offering a novel alternative to the common drugs currently in use. The data also validates the manageable safety profile of Trodelvy, thus making it a good option for a partner candidate for combination with other therapies, including immunotherapy.
The phase III results support the previously reported phase II data that formed the basis of the accelerated approval of Trodelvy.
We remind investors that in April, Trodelvy obtained accelerated approval from the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC), who have received at least two prior therapies for metastatic disease. Trodelvy is the first antibody-drug conjugate (ADC) approved by the FDA specifically for previously-treated mTNBC and also the first FDA-approved anti-Trop-2 ADC.
The drug is also being evaluated for additional indications. The FDA recently granted a Fast Track designation to sacituzumab govitecan for the treatment of adult patients with locally-advanced or metastatic urothelial cancer (mUC).
Meanwhile, Immunomedics also collaborated with few companies for further development of Trodelvy. Itcollaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s (MRK - Free Report) anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company also entered two clinical collaborations. It collaborated with Roche (RHHBY - Free Report) to develop Trodelvy in the front-line setting of mTNBC in combination with the latter’s PD-L1 inhibitor, Tecentriq.
The company has a similar collaboration agreement with AstraZeneca (AZN - Free Report) to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
These collaborations are constant sources of funds for the company.
Immunomedics, Inc. Price
Immunomedics, Inc. price | Immunomedics, Inc. Quote
Zacks Rank
Immunomedics is currently a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all. This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025. Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>